Genmab A (GMAB) Total Liabilities (2019 - 2026)
Genmab A (GMAB) posted Total Liabilities of $6.7 billion for Q1 2026, down 4.73% on a QoQ basis from $7.0 billion in Q4 2025, and up 1.64% year-over-year from $6.6 billion in Q1 2025.
Genmab A (GMAB) Total Liabilities (2019 - 2026) Analysis & Trends
Genmab A's Total Liabilities history runs 6 years deep, the most recent figure standing at $6.7 billion for Q1 2026.
- Quarterly Total Liabilities rose 1.64% year-over-year to $6.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.7 billion (up 1.64% YoY) and the FY2025 annual result came in at $7.0 billion, up 450.2% from the prior year.
- Total Liabilities was $6.7 billion for Q1 2026 at Genmab A, down from $7.0 billion in the prior quarter.
- Across five years, Total Liabilities topped out at $7.0 billion in Q4 2025 and bottomed at $545.0 million in Q4 2023.
- A 4-year average of $3.5 billion and a median of $1.3 billion in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2025 — Total Liabilities jumped 450.2% — and 2026, when it increased 1.64%.
- Genmab A's Total Liabilities stood at $545.0 million in 2023, then soared by 134.31% to $1.3 billion in 2024, then soared by 450.2% to $7.0 billion in 2025, then fell by 4.73% to $6.7 billion in 2026.
- Business Quant data shows GMAB's Total Liabilities at $6.7 billion in Q1 2026, $7.0 billion in Q4 2025, and $1.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 60.46 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 177.22 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 3.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 7.33 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 7.12 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 9.45 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.48 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.62 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 753.82 Mn |
| 10 | Genmab A | 1.89 Bn | 366.92 Mn | 831.00 Mn | 6.69 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.69 Bn |
| Dec 31, 2025 | 7.03 Bn |
| Sep 30, 2025 | 1.27 Bn |
| Jun 30, 2025 | 1.16 Bn |
| Mar 31, 2025 | 6.59 Bn |
| Dec 31, 2024 | 1.28 Bn |
| Dec 31, 2023 | 545.00 Mn |
| Sep 30, 2020 | 3,045,000.00 Bn |
| Dec 31, 2019 | 1,096,000.00 Bn |
| Sep 30, 2019 | 815.67 Mn |